heparin-induced thrombocytopenia - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Infographic showing Galderma’s proposed board appointments of Rosalind Brewer and Petra Rumpf, planned departure of Chief Financial Officer Luigi La Corte, 25.1% constant-currency sales growth and pending $1.5 billion ZO Skin Health acquisition.

Galderma targets December 3 board vote as $1.5bn ZO Skin Health acquisition approaches closing

SentinelOne adds Claude Mythos 5.1 to AI cybersecurity service as $1.22bn recurring revenue supports expansion

Illumina (NASDAQ: ILMN) raises guidance, then plunges 19%. What’s missing?

Alibaba opens two Amsterdam cloud data centres as European AI expansion gains momentum

Read More

Pharma Industry News

CVKD expands clinical pipeline with acquisition of VLX-1005, a Phase 2 12-LOX inhibitor for HIT patients

Discover how Cadrenal Therapeutics’ acquisition of VLX-1005 could reshape treatment options for heparin-induced thrombocytopenia and strengthen its anticoagulation pipeline.

bySoujanya Ravi

December 13, 2025

web analytics